Concepedia

Author

Jon Collins

GlaxoSmithKline (United States)ORCID

Also Known As

Jon Collins, Jon W. Collins

15

Publications

183

Citations

8

H-Index

15

Concepts

All Affiliations

GlaxoSmithKline (United States)Research Triangle Park FoundationRoivant Sciences (United States)
JC

About

Jon Collins is an author at GlaxoSmithKline (United States) specializing in medicine, translational medicine, and autoimmunity.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

55

2

Allergy

1

1

28

3

Clinical Immunology

1

1

28

4

Immunology

1

1

28

5

Pharmacology

1

1

28

Jon Collins

×

6

Publications

143

Citations

6

H-Index

YearCitations

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis

Rosie Z. Yu, Jon Collins, Shannon Hall,

Nucleic Acid Therapeutics

2020

31

RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2-079)

Jon Collins, Lori S. Jones, Michele Snyder,

Neurology

2019

28

A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis

Stephen C. Piscitelli, Ana B. Pavel, Kimberly McHale,

Journal of Investigative Dermatology

2021

27

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma

Chetan Rathi, Jon Collins, Herbert Struemper,

CPT Pharmacometrics & Systems Pharmacology

2021

25

Exposure–Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma

Geraldine Ferron‐Brady, Chetan Rathi, Jon Collins,

Clinical Pharmacology & Therapeutics

2021

22

Population Dose–Response‐Time Analysis of Itch Reduction and Patient‐Reported Tolerability Supports Phase III Dose Selection for Linerixibat

F. Carreño, Eleni Karatza, Rashmi Mehta,

Clinical Pharmacology & Therapeutics

2023

10

Page 1